Mayo Clinic Laboratories has made a strategic investment in Singapore-based Pathology Asia Holdings and its genomics subsidiary LifeStrands Genomics as the companies expand diagnostic and precision-medicine services across Southeast Asia, Australia, and New Zealand.
The companies did not disclose the size of the investment. The partnership deepens an existing relationship between Mayo Clinic Laboratories and Pathology Asia, whose network spans Singapore, Malaysia, Indonesia, Thailand, Vietnam, the Philippines, and Australia.
William Morice II, president and chief executive officer of Mayo Clinic Laboratories, has also been appointed Scientific Adviser to Pathology Asia.
Genomics becomes a central part of the partnership
The collaboration centers on expanding access to molecular and genomic testing through LifeStrands Genomics. The companies said the work will cover areas including inherited conditions, disease-risk assessment, diagnosis, and treatment planning.
LifeStrands operates clinical genomics laboratories in Singapore and Australia, alongside DNA Laboratories. In some markets, the business will operate under the name “LifeStrands in collaboration with Mayo Clinic Laboratories.”
The partnership is intended to bring Mayo’s clinical and laboratory expertise together with Pathology Asia’s regional operating network. That could shorten the path between specialist testing capabilities and healthcare providers that currently need to send samples or refer cases outside their home markets.
Regional diagnostics networks continue to consolidate
Pathology Asia has built a network of pathology and laboratory businesses across the region, including Innoquest, Singapore Diagnostics, TissuPath, Safework Health, LifeStrands Genomics, and DNA Laboratories.
The investment therefore gives Mayo Clinic Laboratories a deeper relationship with an established regional diagnostics platform rather than a single laboratory site. The companies said they also plan joint scientific initiatives, education, and thought leadership around the use of genomics in clinical care.
The transaction fits a broader regional pattern in which diagnostics providers are trying to combine local laboratory networks with more specialized testing, data, and genomic capabilities. Precision medicine depends not only on sequencing or molecular testing capacity, but also on how reliably results can be interpreted and integrated into clinical workflows.
Commercial terms remain undisclosed
The announcement did not disclose ownership percentages, investment value, or detailed financial terms. It also did not specify how quickly new tests or services will become available in each market.
That leaves the practical impact to be measured through future service launches, laboratory integration, physician adoption, and the number of patients able to access testing locally.
For Pathology Asia and LifeStrands, the Mayo relationship adds scientific and brand depth to a regional network already active in several Southeast Asian markets. For Mayo Clinic Laboratories, the investment creates a more direct route into a region where demand for advanced diagnostics is growing alongside private healthcare, oncology, reproductive medicine, and genomic testing.
Beyond telehealth: The rise of real-time, human-aware healthtech in Southeast Asia